Cutera (CUTR) Receives a Buy from Maxim Group

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Cutera (CUTRResearch Report), with a price target of $80.00. The company’s shares closed last Friday at $48.74.

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.8% and a 36.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and Dermata Therapeutics.

Cutera has an analyst consensus of Strong Buy, with a price target consensus of $71.00, representing a 41.3% upside. In a report issued on July 27, Piper Sandler also maintained a Buy rating on the stock with a $65.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $74.38 and a one-year low of $31.62. Currently, Cutera has an average volume of 494.9K.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CUTR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cutera, Inc. provides laser and energy-based aesthetic systems for practitioners, which engages in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners. Its products include Enlighten, TruSculpt, Excel HR, Excel V, and Xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.

Read More on CUTR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More